Loading...
Docoh

Vallon Pharmaceuticals (VLON)

Employees
Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On June 9, 2022, Vallon Pharmaceuticals, Inc. ("the Company" or "Vallon") held its Annual Meeting of Stockholders(the "Annual Meeting"). As of April 14, 2022, the record date for the Annual Meeting, there were 6,812,836 shares of Vallon common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 3,823,241, or approximately 56%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of Vallon common stock are entitled to one vote for each share held and cumulative voting for directors is not permitted. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.

Proposal 1. Election of Directors

The Company’s stockholders elected (i) Mr. David Baker to the Company's Board of Directors, to serve as a Class I director for the remaining two years of the Class’s term or until such person's successor is duly elected and qualified and (ii) each of Dr. Richard Ammer and Ms. Marella Thorell to the Company's Board of Directors, to serve as Class II directors until the Company's 2025 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified. The voting on this proposal is set forth below:

ForWithheldBroker Non-Votes
David Baker2,549,94260,1531,213,146
Marella Thorell2,550,85259,2431,213,146
Richard Ammer2,550,90959,1861,213,146


Joseph Payne and Meenu Karson continue to serve as Class III directors until the Company’s Annual Meeting of Stockholders to be held in 2023.

Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. The voting on this proposal is set forth below:

ForAgainstAbstentions
Ratification of EisnerAmper LLP3,816,7324,2462,263


Proposal 3. Approval, on an Advisory, Non-Binding Basis of the Compensation of the Company's Named Executive Officers

The Company’s stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers for 2021. The voting on this proposal is set forth below:

ForAgainstAbstainBroker Non-Votes
Approval, on an Advisory, Non-Binding Basis of Executive Compensation2,565,89536,7957,4051,213,146


Proposal 4. Vote, on an Advisory, Non-Binding Basis on the Frequency of and Advisory Vote on Executive Compensation.

The Company’s stockholders approved, on an advisory, non-binding basis, the frequency of stockholder votes on the Company’s executive compensation to be one year. The voting on this proposal is set forth below:

1 Year2 Years3 YearsAbstain
Vote, on an Advisory, Non-Binding Basis, of Frequency of Advisory Vote on Executive Compensation2,594,2794,1613,4368,219